Posted by Michael Wonder on 01 Jul 2021
Analysis of launch and post-approval cancer drug pricing, clinical benefit, and policy implications in the US and Europe
1 June 2021 - In this economic evaluation of the US compared with 3 European countries, launch prices of cancer drugs were higher in the US than in Europe; prices frequently increased faster than inflation in the US but decreased on inflation-adjusted terms in Europe.
Launch prices and post launch price increases were not associated with clinical benefit in any country.
